Strides Pharma Science Ltd — earnings calls

Strides Pharma Science reported FY26 revenue of INR48,587 million, up 6.4% year-on-year, with EBITDA of INR925 crores growing 15% and EBITDA margin expanding to 19%. Management attributed the revenue shortfall against expectations to a weaker US flu season and donor funding challenges in access markets, while highlighting 21% growth in Ex-US markets and a shift in revenue mix toward Ex-US business. The company also announced the appointment of Ramaraju, current COO, as Executive Director, and the Board recommended a dividend of INR5 per share.